Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study

Gafanov, R. and Powles, T.B. and Bedke, J. and Stus, V. and Wadde, T.S. and Nosov, D. and Pouliot, F. and Soulières, D. and Melichar, B. and Azevedo, S. and McDermott, R.S. and Vynnychenko, I. and Borchiellini, D. and Markus, M. and Bondarenko, I. and Lin, J. and Burgents, J. and Molife, L. R. and Rini (2021) Subsequent therapy following pembrolizumab + axitinib or sunitinib treatment for advanced renal cell carcinoma (RCC) in the phase III KEYNOTE-426 study. Annals of Oncology, 32 (5). p. 694. ISSN 0923-7534 (Print), 1569-8041 (Electronic)

Text Subsequent therapy following pembrolizumab....pdf Download (100kB)

Abstract

Background: In the phase III KEYNOTE-426 study, pembrolizumab + axitinib showed significant improvement in OS, PFS, and ORR vs sunitinib in patients with RCC. This analysis assessed subsequent treatment in patients enrolled in KEYNOTE-426. Methods: Treatment-naive patients with clear cell RCC, KPS score �70%, and measurable disease (RECIST v1.1) were randomly assigned 1:1 to receive pembrolizumab 200 mg IV every 3 weeks for up to 35 doses + axitinib 5 mg orally twice daily or sunitinib 50 mg once daily (4 weeks on/2 weeks off) until progression, toxicity, or withdrawal. Type of and time to subsequent therapy were assessed. Results: Of patients in the pembrolizumab + axitinib arm and in the sunitinib arm, 81.4% (349/432) and 90.6% of patients (385/429), respectively, discontinued treatment; radiologic or clinical PD was the most common reason for discontinuation in both (pembrolizumab + axitinib: 65.0% [227/349]; sunitinib: 68.1% [262/385]). Of patients who discontinued, 58.5% of patients (204/349) in the pembrolizumab + axitinib arm and 73.0% (281/385) in the sunitinib arm received subsequent therapy (Table). Although a similar proportion of patients in both arms received subsequent therapy with a VEGF/VEGFR inhibitor (pembrolizumab + axitinib: 88.2% [180/204]; sunitinib: 68.7% [193/281]), a greater proportion of patients in the sunitinib arm (74.4% [209/281]) received subsequent PD-1/PD-L1 inhibitor therapy than in the pembrolizumab + axitinib arm (21.6% [44/204]). Of patients in the pembrolizumab + axitinib arm and the sunitinib arm, 32.4% (66/204) and 22.8% (64/281), respectively, received other therapies.

Item Type:	Article
Additional Information:	doi.org/10.1016/j.annonc.2021.08.065
Subjects:	Urology Oncology
Divisions:	Departments > Department of Oncology and Medical Radiology Departments > Department of Urology
Depositing User:	Аліна Чеботарьова
Date Deposited:	21 Oct 2022 07:08
Last Modified:	24 Oct 2022 08:23
URI:	http://repo.dma.dp.ua/id/eprint/7879

Actions (login required)

View Item